|[July 01, 2014]
INVESTOR ALERT: Investigation of Northwest Biotherapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP
LOS ANGELES --(Business Wire)--
Binkow & Goldberg LLP announces that it is investigating
potential claims on behalf of investors of Northwest
Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company")
(NASDAQ:NWBO) concerning possible violations of federal securities laws.
The investigation focuses on the Company's operations and prospects.
Please contact us at (646) 539-8980, or at firstname.lastname@example.org
to discuss this matter. If you inquire by email please include your
mailing address, telephone number and number of shares purchased.
Northwest Biotherapeutics is a biotechnology company engaged in the
discovery and development of immunotherapy products to treat cancers in
the United States and internationally. The Company is involved in the
development of DCVax, a platform technology that uses activated
dendritic cells to mobilize a patient's own immune system to attack
cancer. The investigation is related to an article published by TheStreet.com
on June 19, 2014, alleging that the MD Anderson Cancer Center "issued a
stern rebuke to Northwest Biotherapeutics for making promotional,
unjustified claims about results from an ongoing clinical trial of an
experimental cancer vaccine known as DCVax-Direct." The article further
alleges that the vice president of clinical research at the MD Anderson
Cancer Center stated that claims in certain of the Company's press
releases concerning the DCVax-Direct clinical trials are preliminary and
unconfirmed. Following this news, the price of Northwest Biotherapeutics
shares dropped nearly 20 percent in intraday trading on June 19, 2014.
If you purchased Northwest Biotherapeutics securities, if you have
information or would like to learn more about these claims, or if you
have any questions concerning this announcement or your rights or
interests with respect to these matters, please contact Lesley Portnoy,
Esquire, of Glancy Binkow & Goldberg LLP, 122 East 42nd Street, Suite
2920, New York, NY 10168, at (646) 539-8980, by e-mail to email@example.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To Technology News's Homepage ]